Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Immunodeficiency Evaluation for Chronic Infections in Adults and Older Children Testing Algorithm
Immunodeficiency Evaluation for Chronic Infections in Infants and Children Testing Algorithm
Connective Tissue Disease Testing Algorithm
Clinical Background
The inflammatory myopathies are a group of autoimmune disorders characterized by an inflammatory infiltrate in skeletal muscle and the presence of autoantibodies.
Subgroups of myositis
- Dermatomyositis (DM)
- Polymyositis (PM)
- Inclusion body myositis (IBM)
- Antisynthetase syndrome
- Overlap syndromes
- Amyopathic dermatomyositis
Epidemiology
- Incidence - 2-8/1,000,000
- Age
- DM and PM - 40 to 60 years
- IBM - >50 years
- Antisynthetase - no specific age distribution
- Gender
- DM - F:M; 2:1
- IBM - M:F; 2:1
- Antisynthetase - almost exclusively females
Pathophysiology
- DM is a microangiopathy affecting skin and muscle with deposition of complement causing lysis of endomysial capillaries and muscle ischemia
- In PM and IBM, T-cells invade muscle fibers leading to necrosis via the perforin pathway
Clinical Presentation
- General features
- Presentation of progressive (usually symmetrical) muscle weakness
- Pharyngeal and neck flexion muscles frequently involved, leading to dysphagia
- May have systemic symptoms such as fever, weight loss
- Raynaud phenomenon common
- Dermatomyositis
- Characteristic rash accompanied by muscle weakness
- Blue-purple rash - symmetrical distribution
- Discoloration of upper eyelids with edema (Heliotrope rash)
- Erythema of knuckles with raised violaceous rash (Gottron rash)
- Dilated capillaries at base of fingernails
- Cancer-associated myositis
- Most common with DM
- Increased risk of malignancy (15%) in the following types:
- Ovarian
- Breast
- Melanoma
- Non-Hodgkin lymphoma
- Polymyositis
- Rare in children
- Usually subacute presentation
- May be associated with other autoimmune diseases
- Diagnosis of exclusion - none of the following are present:
- Rash
- Family history of
- Neuromuscular disease
- Endocrinopathy
- Muscular dystrophy
- Known biochemical muscle disorder
- Drug-induced myopathy
- Inclusion body myositis
- May be misdiagnosed as PM
- Associated with other autoimmune diseases 20% of the time
- Small muscles in hand frequently involved
- Antisynthetase syndrome
- Almost exclusively in middle-aged women
- Low grade fevers, mechanic’s hands, pulmonary interstitial disease, Raynaud syndrome
- Mechanic’s hands - hyperkeratosis of the palmic and lateral aspects of the hands
- PM and DM skin features
- Amyopathic DM
- Characteristic cutaneous findings of DM
- No evidence of muscle disease
See Also
Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Immunodeficiency Evaluation for Chronic Infections in Adults and Older Children Testing Algorithm
Immunodeficiency Evaluation for Chronic Infections in Infants and Children Testing Algorithm
Connective Tissue Disease Testing Algorithm
Diagnosis
Diagnosis
- Laboratory testing
- Antibodies to autoantigen Jo-1 (histidyl-RNA synthetase) are found in 18-36% of patients satisfying myositis criteria; however these are not useful in confirming diagnosis
- Nearly all Jo-1 positive patients have lung involvement
- Relationship between Jo-1 antibody titer and disease activity reported but not confirmed
- Rarely found in any other disease states
- DM and mixed connective tissue disease
- May have specific antibody (such as anti PM-Sc1) directed against nucleolar-protein complex
- Aminoacyl - RNA synthetase antibody
- Biopsy
- Muscle biopsy - perivascular and perimysial inflammation in DM and PM
- PM - negative muscle biopsy for IBM
| Distribution of Antibodies in Connective Tissue Disease Types |
| | Systemic Lupus Erythematosus (SLE) | Sjögren Syndrome | Mixed Connective Tissue Disease (MCTD) | Progressive Systemic Sclerosis (PSS) | Scleroderma |
| dsDNA abs | 50-60% | 20-30% | 20-25% | <5% | |
| Histone abs | Idiopathic 18-53% Drug-induced 80-95% | | <20% | <20% | <20% |
| RNP | 20-30% | | 95-100% | 15-25% | 5-10% |
| Scl-70 | | | | 25% | 20-60% |
| SSA | ANA positive patients 30-40% | 70-75% | | 5-10% | |
| SSB | 15-25% | 50-60% | | 5-10% | |
| Jo-1 abs | Found in polymyositis, dermatomyositis, myositis associated with rheumatic disease |
Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Immunodeficiency Evaluation for Chronic Infections in Adults and Older Children Testing Algorithm
Immunodeficiency Evaluation for Chronic Infections in Infants and Children Testing Algorithm
Connective Tissue Disease Testing Algorithm
| Tests |  |
Tests generally appear in the order most useful for common clinical situations
| Test name: Anti-Nuclear Antibodies (ANA), IgG Screen with Reflex to IFA Titer
|
| ARUP #: 0050080 |
| Methodology: Enzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody
|
| Use:
First line test for connective tissue disease screening |
| Limitations: |
| Follow-up: Recommend cutaneous direct immunofluorescence testing of active edge of new lesion (lesional biopsy) if dermatologic manifestations are present |
| Test name: Jo-1 Antibody, IgG
|
| ARUP #: 0099592 |
| Methodology: Multi-Analyte Fluorescent Detection
|
| Use: Order as secondary screen based on results of ANA, myositis-specific antibodies |
| Limitations: |
| Follow-up:
Recommend cutaneous direct immunofluorescence testing of active edge of new lesion (lesional biopsy) if dermatologic manifestations are present
|
| Test name: SSA (Ro) (ENA) Antibody, IgG
|
| ARUP #: 0050691 |
| Methodology: Multi-Analyte Fluorescent Detection
|
| Use: Order as secondary screen based on results of ANA, myositis-associated antibodies |
| Test name: PM-Scl Antibody, ID
|
| ARUP #: 0099591 |
| Methodology: Immunodiffusion
|
| Use: Order as secondary screen based on results of ANA, myositis-associated antibodies |
| Test name: RNP (U1) (Ribonucleic Protein) (ENA) Antibody, IgG
|
| ARUP #: 0050470 |
| Methodology: Multi-Analyte Fluorescent Detection
|
| Use: Order as secondary screen based on results of ANA, myositis-associated antibodies |
| Test name: SSB (La) (ENA) Antibody, IgG
|
| ARUP #: 0050692 |
| Methodology: Multi-Analyte Fluorescent Detection
|
| Use: Order as secondary screen based on results of ANA, myositis-associated antibodies |
Additional Tests Available
| Test name: Aldolase, Serum
|
| ARUP #: 0020012 |
| Methodology: Enzymatic
|
| Comments: |
| Test name: Extractable Nuclear Antigen Antibodies (RNP, Smith, SSA, & SSB)
|
| ARUP #: 0050652 |
| Methodology: Multi-Analyte Fluorescent Detection
|
| Comments: |
Additional Information
When cell culture substrates (Hep-2 cells) are used in ANA testing, ANA incidence is
- >80% in SLE, Sjögren syndrome and scleroderma
- 50-80% in adult rheumatoid arthritis and mixed connective tissue disease
- About 40% in juvenile rheumatoid arthritis
References
General References
Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity.
2006;
39(
3):
161-170.
Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol.
2004;
18(
3):
331-344.
Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet.
2003;
362(
9388):
971-982.
Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol.
2004;
17(
5):
561-567.
Jaskowski TD, Schroder C, Martins TB, Mouritsen L, Hill HR. Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens. J Clin Lab Anal.
1995;
9(
3):
166-172.
Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci.
2005;
1050:
217-228.
Nirmalananthan N, Holton JL, Hanna MG. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol.
2004;
16(
6):
684-691.
Medical Reviewers
Hill, Harry R., M.D. Group Medical Director, Laboratory of Immunology, ARUP Laboratories, and Executive Director of the ARUP Institute for Clinical and Experimental Pathology; Professor and Division Head, Clinical Pathology, University of Utah
Tebo, Anne E., Ph.D. Assistant Medical Director, Immunology at ARUP Laboratories; Clinical Assistant Professor, Clinical Pathology, University of Utah
Comprehensive Review: November 2007
Last Update: July 2008